DT&CRO Co., Ltd.
KKRX:3839302,145.00
KRW
-170.00
(-7.34%)
ISIN
KR7383930005
Return %
Stock
S&P 500
1Y
-27.29
14.39
3Y
-47.75
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Chae-Kyu Park
- Full Time Employees
- 314
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Yongin-si South Korea
- IPO Date
- Nov 11, 2022
- Website
- dtncro.com
- Similar Companies
- Business
- DT&CRO Co., Ltd. operates as a comprehensive contract research organization providing full-scope non-clinical and clinical development services for the pharmaceutical, biopharmaceutical, medical device, health functional food, and cosmetics industries. The company offers end-to-end drug discovery and development solutions organized across specialized service divisions: non-clinical efficacy and pharmacology services, including in vitro and in vivo screening, pharmacokinetic and pharmacodynamic profiling, and disease model evaluations; Good Laboratory Practice-compliant toxicology and safety pharmacology testing, encompassing single-dose and repeated-dose toxicity, genotoxicity, reproductive toxicity, and carcinogenicity studies; bioanalytical services utilizing liquid chromatography-tandem mass spectrometry and advanced immunoassay platforms for small-molecule and large-molecule pharmacokinetic analysis, biomarker validation, and immunogenicity testing; full-service clinical trial management spanning Phase I through Phase IV human trials, bioequivalence studies, investigator-initiated trials, and post-marketing surveillance; clinical operations and consulting, comprising clinical protocol design, regulatory affairs support for Investigational New Drug and New Drug Application filings, medical writing, clinical site management, monitoring, data management, and biostatistics; and safety and efficacy evaluation services tailored for medical devices, cosmetics, and functional foods to support domestic and international regulatory approvals. In recent developments, DT&CRO Co., Ltd. has expanded its Good Laboratory Practice testing capacity and bioanalytical infrastructure to support emerging drug modalities such as antibody-drug conjugates, nucleic acid therapeutics, and cell and gene therapies. The company has also entered into strategic collaborative alliances with domestic and global biotechnology companies and medical centers to accelerate smart clinical trials, digital health-integrated monitoring, and cross-border regulatory pathways across Asian and Western markets. Founded in 2017, DT&CRO Co., Ltd. is headquartered in Yongin-si, Gyeonggi-do, South Korea, and operates as an affiliate of Dt&C Group.